Day One Announces Oversubscribed $175.0 Million Private Placement
Day One Biopharmaceuticals (Nasdaq: DAWN) has secured an oversubscribed $175.0 million private placement of its securities. The placement includes 10,551,718 shares of common stock at $14.50 per share and 1,517,241 pre-funded warrants at $14.4999 each. Notable investors include Fairmount, Braidwell LP, Deerfield Management, and Wellington Management. The company plans to use the proceeds to fund commercial capabilities, research and development, potential acquisitions, and working capital. The private placement is expected to close on August 1, 2024, subject to customary conditions. J.P. Morgan, TD Cowen, Goldman Sachs & Co. , and Piper Sandler are acting as joint placement agents.
Day One Biopharmaceuticals (Nasdaq: DAWN) ha ottenuto un collocamento privato sovrascritto di 175,0 milioni di dollari per i suoi titoli. Il collocamento include 10.551.718 azioni ordinarie a 14,50 dollari per azione e 1.517.241 warrant pre-finanziati a 14,4999 dollari ciascuno. Tra gli investitori di rilievo ci sono Fairmount, Braidwell LP, Deerfield Management e Wellington Management. L'azienda prevede di utilizzare i proventi per finanziare capacità commerciali, ricerca e sviluppo, potenziali acquisizioni e capitale circolante. Si prevede che il collocamento privato si concluda il 1° agosto 2024, soggetto a condizioni abituali. J.P. Morgan, TD Cowen, Goldman Sachs & Co. e Piper Sandler stanno agendo come agenti di collocamento congiunti.
Day One Biopharmaceuticals (Nasdaq: DAWN) ha asegurado un colocación privada sobre suscrita de 175,0 millones de dólares de sus valores. La colocación incluye 10.551.718 acciones ordinarias a 14,50 dólares por acción y 1.517.241 garantías pre-financiadas a 14,4999 dólares cada una. Los inversores notables incluyen a Fairmount, Braidwell LP, Deerfield Management y Wellington Management. La compañía planea utilizar los ingresos para financiar capacidades comerciales, investigación y desarrollo, adquisiciones potenciales y capital de trabajo. Se espera que la colocación privada cierre el 1 de agosto de 2024, sujeto a condiciones habituales. J.P. Morgan, TD Cowen, Goldman Sachs & Co. y Piper Sandler actúan como agentes de colocación conjuntos.
데이 원 바이오제약(Nasdaq: DAWN)이 1억 7500만 달러의 초과 구독 프라이빗 플레시싱을 확보했습니다. 이번 플레시싱에는 10,551,718주가 주당 14.50달러에 발행치며, 1,517,241개의 사전 자금조달 관련 증서가 각각 14.4999달러에 포함됩니다. 주목할 만한 투자자로는 Fairmount, Braidwell LP, Deerfield Management 및 Wellington Management가 있습니다. 회사는 상업 능력, 연구 및 개발, 잠재적 인수 및 운영 자본에 자금을 사용할 계획입니다. 이번 프라이빗 플레시싱은 2024년 8월 1일에 클로즈될 예정이며, 일반적인 조건에 따라 진행됩니다. J.P. 모건, TD Cowen, 골드만삭스 & Co. 그리고 파이퍼 샌들러가 공동 배치 에이전트로 활동하고 있습니다.
Day One Biopharmaceuticals (Nasdaq: DAWN) a sécurisé un placement privé sursouscrit de 175 millions de dollars de ses titres. Ce placement comprend 10.551.718 actions ordinaires à 14,50 dollars par action et 1.517.241 bons de souscription préfinancés à 14,4999 dollars chacun. Parmi les investisseurs notables figurent Fairmount, Braidwell LP, Deerfield Management et Wellington Management. La société prévoit d'utiliser les revenus pour financer des capacités commerciales, la recherche et le développement, des acquisitions potentielles et le fonds de roulement. Le placement privé devrait se clore le 1er août 2024, sous réserve des conditions habituelles. J.P. Morgan, TD Cowen, Goldman Sachs & Co. et Piper Sandler agissent en tant qu'agents de placement conjoints.
Day One Biopharmaceuticals (Nasdaq: DAWN) hat sich eine überzeichnete Privatplatzierung von 175,0 Millionen US-Dollar seiner Wertpapiere gesichert. Die Platzierung umfasst 10.551.718 Stammaktien zu je 14,50 USD pro Aktie und 1.517.241 vorfinanzierte Optionsscheine zu je 14,4999 USD. Zu den bemerkenswerten Investoren zählen Fairmount, Braidwell LP, Deerfield Management und Wellington Management. Das Unternehmen plant, die Einnahmen zur Finanzierung von Geschäftsfähigkeiten, Forschung und Entwicklung, potenziellen Akquisitionen und Betriebskapital zu verwenden. Die Privatplatzierung wird voraussichtlich am 1. August 2024 abgeschlossen, vorbehaltlich der üblichen Bedingungen. J.P. Morgan, TD Cowen, Goldman Sachs & Co. und Piper Sandler fungieren als gemeinsame Platzierungsagenten.
- Secured $175.0 million in oversubscribed private placement
- Participation from both new and existing high-profile investors
- Funds to be used for commercial capabilities, R&D, and potential strategic acquisitions
- Potential dilution of existing shareholders due to new share issuance
Insights
Day One Biopharmaceuticals' successful $175 million private placement is a significant financial milestone that strengthens the company's position in the competitive biotech landscape. The oversubscribed nature of the placement indicates strong investor confidence in Day One's potential. With shares priced at
The participation of both new and existing investors, including renowned firms like Deerfield Management and Wellington Management, adds credibility to Day One's business model and growth prospects. The inclusion of pre-funded warrants provides additional flexibility for certain investors while ensuring immediate capital infusion for the company.
The intended use of proceeds for commercial capabilities, R&D and potential acquisitions suggests a balanced approach to growth. This capital raise significantly bolsters Day One's financial position, potentially extending their cash runway and reducing the need for dilutive financing in the near term. However, investors should monitor the company's burn rate and progress in commercialization efforts to assess the long-term impact of this capital injection.
The successful private placement by Day One Biopharmaceuticals reflects a broader trend in the biotech sector, where investors are showing renewed interest in companies with promising pipelines and commercial potential. The oversubscription of the placement, especially in the current market conditions, is a strong indicator of investor appetite for innovative biotech firms.
The diverse investor base, including specialized healthcare funds and large investment management firms, suggests a broad market recognition of Day One's potential. This could potentially lead to increased institutional ownership and improved liquidity for the stock in the future.
The pricing of the shares at
The timing of this capital raise, just before the company's Q2 earnings report, could indicate management's confidence in upcoming results or pipeline developments. Investors should closely monitor the company's upcoming announcements and financial reports to gauge the full impact of this capital infusion on Day One's growth trajectory and market position.
The private placement structure chosen by Day One Biopharmaceuticals is a common approach for biotech companies seeking to raise capital quickly while avoiding the lengthy process and regulatory scrutiny associated with a public offering. By relying on Section 4(a)(2) of the Securities Act, the company can efficiently raise funds from accredited investors without immediate SEC registration.
The inclusion of pre-funded warrants alongside common stock is a strategic move that provides flexibility for investors who may be subject to ownership limitations or prefer certain tax treatments. These warrants, with their nominal exercise price of
Day One's commitment to file a registration statement within 30 days of closing is a standard practice that ensures future liquidity for the private placement investors. This also signals the company's intention to maintain transparency and comply with SEC regulations.
From a governance perspective, the participation of existing investors alongside new ones in this placement could be seen as a positive sign of ongoing support from current stakeholders. However, investors should be aware that such private placements can potentially lead to changes in voting power and control dynamics within the company.
The use of multiple placement agents (J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Piper Sandler) suggests a comprehensive approach to investor outreach and could indicate a competitive process in securing favorable terms for the company.
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately
The private placement includes participation from both new and existing investors including Fairmount, Braidwell LP, Deerfield Management, Wellington Management, Frazier Life Sciences and Access Biotechnology, as well as large investment management firms and several healthcare dedicated funds.
The private placement will be for 10,551,718 shares of common stock at a price of
The private placement is expected to close on August 1, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds from the private placement, together with its existing cash, cash equivalents and short-term investments, to fund investment in its commercial capabilities, continued research and development activities, potential strategic acquisitions or licensing of complementary businesses or technologies, working capital and other general corporate purposes.
J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Piper Sandler are acting as joint placement agents for the private placement.
The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and are being issued and sold in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Day One has agreed to file a registration statement to register the resale of the securities within 30 days of the closing of the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program.
Day One is based in Brisbane, California.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements regarding the closing of the private placement, registration of the shares of common stock being issued and sold in the private placement, Day One’s use of the proceeds from the private placement, Day One’s plans to develop cancer therapies, including DAY301, expectations regarding planned and current clinical trials and the ability of tovorafenib to treat pLGG or related indications.
Statements including words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.
Forward-looking statements are subject to risks and uncertainties that may cause Day One’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Day One’s ability to develop, obtain regulatory approval for or commercialize any product candidate, Day One’s ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of inflation, rising interest rates, instability in the global banking system, geopolitical conflicts and the sufficiency of Day One’s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
What is the size of Day One Biopharmaceuticals' (DAWN) recent private placement?
At what price were DAWN shares sold in the private placement?
When is the expected closing date for DAWN's private placement?
How does Day One Biopharmaceuticals (DAWN) plan to use the proceeds from the private placement?
